Drug intelligence / Profile preview

afasevikumab

Development stage: Discontinued
Lead developer: Genentech
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Subcutaneous

Overview

Afasevikumab is a fully human monoclonal IgG1κ antibody that targets and neutralizes both interleukin 17A (IL17A) and interleukin 17F (IL17F). It was originally developed by NovImmune SA and later by Genentech for the treatment of inflammatory diseases such as autoimmune disorders. The drug acts as an inhibitor of IL-17A and IL-17F proteins, which are key cytokines involved in the pathogenesis of various immune-mediated inflammatory conditions. Afasevikumab reached clinical development but has since been discontinued for all indications[1][3][4][5].

Other names: afasevikumab

Targets

IL-17A (Interleukin-17A)IL17F (Interleukin 17F)

Beyond the preview

Go deeper on afasevikumab.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on afasevikumab.

Explore the full profile